Getinge (OTCMKTS:GNGBY) Posts Earnings Results

Getinge (OTCMKTS:GNGBY) issued its earnings results on Wednesday. The company reported $0.32 earnings per share for the quarter, Zacks reports. Getinge had a return on equity of 11.12% and a net margin of 7.81%.

Getinge Price Performance

Shares of OTCMKTS:GNGBY opened at $26.23 on Wednesday. The company’s fifty day moving average price is $25.11 and its 200 day moving average price is $22.69. Getinge has a 12 month low of $18.99 and a 12 month high of $26.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.31 and a quick ratio of 0.74. The firm has a market capitalization of $7.14 billion, a P/E ratio of 24.98 and a beta of 0.95.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on GNGBY shares. Zacks Research cut Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 17th. Nordea Equity Research downgraded Getinge from a “buy” rating to a “hold” rating in a report on Monday, August 31st. Pareto Securities lowered shares of Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 24th. Finally, UBS Group began coverage on shares of Getinge in a research note on Wednesday, September 2nd. They issued a “hold” rating on the stock. Four analysts have rated the stock with a Hold rating. According to data from MarketBeat, the company currently has a consensus rating of “Hold”.

About Getinge

Getinge AB is a Sweden-based medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support patient care, surgical procedures, infection prevention and the development and production of pharmaceuticals and other medical products.

The company’s portfolio includes equipment for intensive care and cardiovascular procedures, operating-room systems, surgical instruments, sterilization and disinfection solutions, and products used in laboratories and biopharmaceutical manufacturing.